ArticlePregnancy (Hoboken, N.J.)2025
Intramuscular methylergonovine to decrease blood loss during cesarean delivery for twins: A triple-blinded placebo-controlled randomized trial.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Our objective was to evaluate whether prophylactic administration of intramuscular (IM) methylergonovine after cord clamping reduces blood loss during planned cesarean delivery (CD) of twin pregnancies. Method: This single-center randomized placebo-controlled triple-blinded trial compared the effects of IM methylergonovine versus saline placebo control on maternal blood loss at CD. Pregnant individuals with twin gestations at ≥ 34 weeks of gestation undergoing planned CD were enrolled. Methylergonovine or saline placebo was administered immediately after umbilical cord clamping of the second twin in addition to standard oxytocin prophylaxis. The primary outcome was a change in mean maternal hemoglobin (Hgb) level from preoperative to postoperative day 1 (POD 1). Secondary outcomes include intraoperative blood loss, additional uterotonic use, and rates of postpartum hemorrhage and transfusion. We planned to enroll 66 patients to detect a standard deviation (SD) greater drop in postoperative maternal Hgb, assuming -1.40 (± 0.83) g/dL Hgb difference after planned CDs (90% power, alpha 0.05). Pearson chi-square test, Fisher's exact test, Results: A total of 66 patients (33 methylergonovine and 33 placebo) were randomized. There were no demographic differences between methylergonovine and placebo groups. Median gestational age at delivery was 37 weeks for both groups. Mean Hgb drop on POD 1 was 1.1 g/dL (SD 0.7 g/dL) for methylergonovine and 2.1 g/dL (SD 0.9 g/dL) for placebo ( Conclusion: Prophylactic IM methylergonovine administered after umbilical cord clamping during twin CD significantly reduced intraoperative blood loss and hemoglobin drop on POD 1. These data support further study of methylergonovine as a preventative treatment strategy at the time of twin CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.